Clinical Trial Update: Pharmacokinetics of Islatravir in Participants With Severe Renal Impairment (MK-8591-026) [Phase 1]

View source ↗

Summary

Phase 1 PK study evaluating islatravir (MK-8591) pharmacokinetics in participants with severe renal impairment completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Islatravir (Islatravir)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Human Immunodeficiency Virus (HIV) Infection | Phase 1 | Status: COMPLETED | Results posted: 2021-10-28